Wheeler Bio Announces Closing of $31 Million Series A Round Supporting its Clinical (CGMP) Drug Substance Manufacturing Facility in Oklahoma City

Wheeler Bio, Inc., a boutique contract development and manufacturing organization specializing in process development and small batch CGMP production of therapeutic antibodies, announced the closing of their Series A financing round.